ClinicalTrials.gg

Program

BTK Degrader ABBV-101

Its studies are mostly in Hematologic Neoplasms, led by AbbVie.

Furthest: phase 1, since Feb 22, 20232 company-led studies, 1 open or runningNext primary completion: Mar 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie21 open or runningphase 1since Feb 22, 2023Feb 22, 2023Mar 2031phase 1 · NCT05753501

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 22, 2023First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05753501 · 135 enrolled · United States, Canada, France and more
  2. Mar 14, 2025Phase 1 study in Healthy VolunteerNCT06887010 · 17 enrolled · United States

Ahead

  1. Mar 2031Primary completion: phase 1 study in Hematologic NeoplasmsNCT05753501

TargetBeta

BTK →read by rule
“An orally bioavailable, targeted degrader of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) comprised of an E3 ubiquitin ligase binding moiety ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06887010Healthy Volunteer · United States1CompletedSep 16, 202517
NCT05753501Hematologic Neoplasms · United States, Canada, France and more1Active, not recruitingMar 2031135

How it is read

Names in the registry

  • “ABBV-101”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.